Cargando…
Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechan...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151513/ https://www.ncbi.nlm.nih.gov/pubmed/21826264 http://dx.doi.org/10.1155/2011/680194 |
_version_ | 1782209625220710400 |
---|---|
author | Bellino, Silvio Bozzatello, Paola Rinaldi, Camilla Bogetto, Filippo |
author_facet | Bellino, Silvio Bozzatello, Paola Rinaldi, Camilla Bogetto, Filippo |
author_sort | Bellino, Silvio |
collection | PubMed |
description | Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic fluctuations and antidopaminergic effects. The aim of this study is to evaluate efficacy and safety of paliperidone ER in BPD patients. 18 outpatients with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3–6 mg/day). They were assessed at baseline, week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI), and the Barratt Impulsiveness Scale (BIS-11). Adverse events were evaluated with the DOTES. Paliperidone ER was shown to be effective and well tolerated in reducing severity of global symptomatology and specific BPD symptoms, such as impulsive dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials. |
format | Online Article Text |
id | pubmed-3151513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31515132011-08-08 Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability Bellino, Silvio Bozzatello, Paola Rinaldi, Camilla Bogetto, Filippo Depress Res Treat Research Article Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic fluctuations and antidopaminergic effects. The aim of this study is to evaluate efficacy and safety of paliperidone ER in BPD patients. 18 outpatients with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3–6 mg/day). They were assessed at baseline, week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI), and the Barratt Impulsiveness Scale (BIS-11). Adverse events were evaluated with the DOTES. Paliperidone ER was shown to be effective and well tolerated in reducing severity of global symptomatology and specific BPD symptoms, such as impulsive dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials. Hindawi Publishing Corporation 2011 2011-08-04 /pmc/articles/PMC3151513/ /pubmed/21826264 http://dx.doi.org/10.1155/2011/680194 Text en Copyright © 2011 Silvio Bellino et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bellino, Silvio Bozzatello, Paola Rinaldi, Camilla Bogetto, Filippo Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability |
title | Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability |
title_full | Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability |
title_fullStr | Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability |
title_full_unstemmed | Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability |
title_short | Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability |
title_sort | paliperidone er in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151513/ https://www.ncbi.nlm.nih.gov/pubmed/21826264 http://dx.doi.org/10.1155/2011/680194 |
work_keys_str_mv | AT bellinosilvio paliperidoneerinthetreatmentofborderlinepersonalitydisorderapilotstudyofefficacyandtolerability AT bozzatellopaola paliperidoneerinthetreatmentofborderlinepersonalitydisorderapilotstudyofefficacyandtolerability AT rinaldicamilla paliperidoneerinthetreatmentofborderlinepersonalitydisorderapilotstudyofefficacyandtolerability AT bogettofilippo paliperidoneerinthetreatmentofborderlinepersonalitydisorderapilotstudyofefficacyandtolerability |